Pharmaceuticals Production Targeted Protein Degradation 
The Pharma Data
DECEMBER 16, 2020
Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.
Sygnature Discovery
SEPTEMBER 25, 2023
Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 21, 2020
Targeted protein degradation (TPD) is an approach whereby the body’s natural process for degrading proteins is diverted using small molecule drugs to eliminate disease-causing proteins. . TOKYO and CAMBRIDGE, England , Dec. No further financial details are disclosed. Forward-looking statements.
The Pharma Data
JANUARY 31, 2021
In addition to Metrion, these collaborations with Captor Therapeutics in targeted protein degradation and with PharmEnable to access proprietary artificial intelligence-enabled and medicinal chemistry technologies are a key factor to drive our future growth ambitions.” Forward-looking statements.
Drug Target Review
OCTOBER 4, 2023
Nicolas also has experience in both antibody production and small molecule synthesis from positions held at Fusion Antibodies and Evotec. Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4 | ACS Chemical Biology. 102 , 1–6 (2016). link] Park H-K, et al.
Expert insights. Personalized for you.
40 
Let's personalize your content